• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鼻腔内接种流感病毒载体 COVID-19 疫苗可抑制仓鼠的 SARS-CoV-2 炎症反应。

Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters.

机构信息

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health & School of Life Sciences, Xiamen University, 361102, Xiamen, Fujian, China.

Tsinghua-Peking Center for Life Sciences, Laboratory of Dynamic Immunobiology, School of Medicine, Tsinghua University, 100084, Beijing, China.

出版信息

Nat Commun. 2023 Jul 11;14(1):4117. doi: 10.1038/s41467-023-39560-9.

DOI:10.1038/s41467-023-39560-9
PMID:37433761
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10336035/
Abstract

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and "anatomical escape" characteristics threaten the effectiveness of current coronavirus disease 2019 (COVID-19) vaccines. There is an urgent need to understand the immunological mechanism of broad-spectrum respiratory tract protection to guide broader vaccines development. Here we investigate immune responses induced by an NS1-deleted influenza virus vectored intranasal COVID-19 vaccine (dNS1-RBD) which provides broad-spectrum protection against SARS-CoV-2 variants in hamsters. Intranasal delivery of dNS1-RBD induces innate immunity, trained immunity and tissue-resident memory T cells covering the upper and lower respiratory tract. It restrains the inflammatory response by suppressing early phase viral load post SARS-CoV-2 challenge and attenuating pro-inflammatory cytokine (Il6, Il1b, and Ifng) levels, thereby reducing excess immune-induced tissue injury compared with the control group. By inducing local cellular immunity and trained immunity, intranasal delivery of NS1-deleted influenza virus vectored vaccine represents a broad-spectrum COVID-19 vaccine strategy to reduce disease burden.

摘要

严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）变体的出现和“解剖逃逸”特征威胁着当前 2019 年冠状病毒病（COVID-19）疫苗的有效性。迫切需要了解广谱呼吸道保护的免疫机制，以指导更广泛的疫苗开发。在这里，我们研究了由缺失 NS1 的流感病毒载体鼻内 COVID-19 疫苗（dNS1-RBD）引起的免疫反应，该疫苗在仓鼠中提供针对 SARS-CoV-2 变体的广谱保护。鼻内递送 dNS1-RBD 可诱导先天免疫、训练免疫和组织驻留记忆 T 细胞，覆盖上呼吸道和下呼吸道。它通过抑制 SARS-CoV-2 挑战后早期病毒载量并降低促炎细胞因子（Il6、Il1b 和 Ifng）水平来抑制炎症反应，从而与对照组相比减少过度免疫诱导的组织损伤。通过诱导局部细胞免疫和训练免疫，缺失 NS1 的流感病毒载体疫苗的鼻内递送代表了一种减少疾病负担的广谱 COVID-19 疫苗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/f7290757bad8/41467_2023_39560_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/7c16ffa4bafa/41467_2023_39560_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/c053b027bd3e/41467_2023_39560_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/be0b3f6ecc38/41467_2023_39560_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/dae2e58a6ffc/41467_2023_39560_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/e5a2fffd3e2c/41467_2023_39560_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/a67e55be50fa/41467_2023_39560_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/f7290757bad8/41467_2023_39560_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/7c16ffa4bafa/41467_2023_39560_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/c053b027bd3e/41467_2023_39560_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/be0b3f6ecc38/41467_2023_39560_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/dae2e58a6ffc/41467_2023_39560_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/e5a2fffd3e2c/41467_2023_39560_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/a67e55be50fa/41467_2023_39560_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae4/10336035/f7290757bad8/41467_2023_39560_Fig7_HTML.jpg

相似文献

1
Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters.鼻腔内接种流感病毒载体 COVID-19 疫苗可抑制仓鼠的 SARS-CoV-2 炎症反应。
Nat Commun. 2023 Jul 11;14(1):4117. doi: 10.1038/s41467-023-39560-9.
2
An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.鼻腔内接种流感病毒载体疫苗可预防 SARS-CoV-2 在小鼠和仓鼠呼吸道组织中的复制。
Nat Commun. 2023 Apr 12;14(1):2081. doi: 10.1038/s41467-023-37697-1.
3
Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters.鼻内流感载体新冠疫苗在仓鼠中对新冠病毒XBB变体具有广泛的保护作用。
PNAS Nexus. 2024 May 3;3(5):pgae183. doi: 10.1093/pnasnexus/pgae183. eCollection 2024 May.
4
A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2.一种基于减毒活病毒的鼻内新型冠状病毒肺炎疫苗能对严重急性呼吸综合征冠状病毒2提供快速、持久且广泛的保护。
Sci Bull (Beijing). 2022 Jul 15;67(13):1372-1387. doi: 10.1016/j.scib.2022.05.018. Epub 2022 May 26.
5
Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza.以活减流感疫苗病毒表达 SARS-CoV-2 受体结合域作为设计针对 COVID-19 和流感双价疫苗的策略。
Virol J. 2024 Apr 9;21(1):82. doi: 10.1186/s12985-024-02350-w.
6
Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.用双流感/新冠单复制病毒载体进行黏膜免疫可保护仓鼠免受新冠病毒攻击。
Vaccine. 2024 Apr 19;42(11):2770-2780. doi: 10.1016/j.vaccine.2024.03.040. Epub 2024 Mar 20.
7
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于减毒流感病毒载体的鼻内 SARS-CoV-2 疫苗在成年人中的安全性和免疫原性：随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Respir Med. 2022 Aug;10(8):749-760. doi: 10.1016/S2213-2600(22)00131-X. Epub 2022 May 26.
8
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.鼻腔内纳米乳佐剂 S-2P 疫苗在仓鼠中显示出保护作用，并在小鼠中诱导全身性、细胞介导和黏膜免疫。
PLoS One. 2022 Nov 2;17(11):e0272594. doi: 10.1371/journal.pone.0272594. eCollection 2022.
9
Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.减毒活 YF17D 载体 COVID-19 疫苗可预防小鼠和仓鼠模型中的致死性黄热病病毒感染。
EBioMedicine. 2022 Sep;83:104240. doi: 10.1016/j.ebiom.2022.104240. Epub 2022 Aug 27.
10
Characterization of Immune Response Diversity in Rodents Vaccinated with a Vesicular Stomatitis Virus Vectored COVID-19 Vaccine.用水疱性口炎病毒载体 COVID-19 疫苗对啮齿动物进行免疫接种的免疫反应多样性特征。
Viruses. 2022 May 24;14(6):1127. doi: 10.3390/v14061127.

引用本文的文献

1
Development of COVID-19 Vaccine Candidates Using Attenuated Recombinant Vesicular Stomatitis Virus Vectors with M Protein Mutations.利用具有M蛋白突变的减毒重组水疱性口炎病毒载体开发COVID-19候选疫苗
Viruses. 2025 Jul 30;17(8):1062. doi: 10.3390/v17081062.
2
Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines.联合疫苗以及流感病毒与SARS-CoV-2疫苗联合接种的进展。
Front Immunol. 2025 Jun 25;16:1578733. doi: 10.3389/fimmu.2025.1578733. eCollection 2025.
3
Chimeric hemagglutinin and M2 mRNA vaccine for broad influenza subtype protection.

本文引用的文献

1
Covid-19: virology, variants, and vaccines.新型冠状病毒肺炎：病毒学、变种与疫苗
BMJ Med. 2022 Apr 1;1(1):e000040. doi: 10.1136/bmjmed-2021-000040. eCollection 2022.
2
Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses.重新思考针对冠状病毒、流感病毒和其他呼吸道病毒的下一代疫苗。
Cell Host Microbe. 2023 Jan 11;31(1):146-157. doi: 10.1016/j.chom.2022.11.016.
3
Recent insights into innate immune nucleic acid sensing during viral infection.病毒感染过程中先天免疫核酸感应的最新认识。
用于广泛流感亚型保护的嵌合血凝素和M2 mRNA疫苗。
NPJ Vaccines. 2025 Jun 5;10(1):113. doi: 10.1038/s41541-025-01178-x.
4
Viral Infections in Elderly Individuals: A Comprehensive Overview of SARS-CoV-2 and Influenza Susceptibility, Pathogenesis, and Clinical Treatment Strategies.老年人中的病毒感染：SARS-CoV-2和流感易感性、发病机制及临床治疗策略的全面概述
Vaccines (Basel). 2025 Apr 21;13(4):431. doi: 10.3390/vaccines13040431.
5
Innovations, Challenges, and Future Prospects for Combination Vaccines Against Human Infections.用于预防人类感染的联合疫苗的创新、挑战及未来前景
Vaccines (Basel). 2025 Mar 21;13(4):335. doi: 10.3390/vaccines13040335.
6
A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3-17 years.一项针对3至17岁儿童的鼻内SARS-CoV-2疫苗dNS1-RBD的随机I期试验。
NPJ Vaccines. 2025 Mar 17;10(1):50. doi: 10.1038/s41541-025-01096-y.
7
Exploring the standardization of human nasal antibody measurements.探索人类鼻腔抗体测量的标准化。
Emerg Microbes Infect. 2025 Dec;14(1):2475822. doi: 10.1080/22221751.2025.2475822. Epub 2025 Mar 17.
8
The applications of live attenuated influenza a virus with modified NS1 gene.具有修饰NS1基因的甲型流感病毒减毒活疫苗的应用。
Mol Ther Nucleic Acids. 2025 Feb 1;36(1):102471. doi: 10.1016/j.omtn.2025.102471. eCollection 2025 Mar 11.
9
Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine.通过鼻内给予HA嵌合多表位纳米颗粒疫苗对同源和异源流感病毒的交叉保护作用。
J Nanobiotechnology. 2025 Feb 4;23(1):77. doi: 10.1186/s12951-025-03122-6.
10
Mucosal Immunization with an Influenza Vector Carrying SARS-CoV-2 N Protein Protects Naïve Mice and Prevents Disease Enhancement in Seropositive Th2-Prone Mice.用携带SARS-CoV-2 N蛋白的流感病毒载体进行黏膜免疫可保护未感染小鼠，并预防血清阳性且倾向于Th2反应的小鼠出现疾病加重。
Vaccines (Basel). 2024 Dec 28;13(1):15. doi: 10.3390/vaccines13010015.
Curr Opin Immunol. 2022 Oct;78:102250. doi: 10.1016/j.coi.2022.102250. Epub 2022 Oct 6.
4
Monocyte-derived alveolar macrophages autonomously determine severe outcome of respiratory viral infection.单核细胞衍生的肺泡巨噬细胞自主决定呼吸道病毒感染的严重结局。
Sci Immunol. 2022 Jul;7(73):eabj5761. doi: 10.1126/sciimmunol.abj5761. Epub 2022 Jul 1.
5
Antibody-mediated neutralization of SARS-CoV-2.抗体介导的 SARS-CoV-2 中和作用。
Immunity. 2022 Jun 14;55(6):925-944. doi: 10.1016/j.immuni.2022.05.005. Epub 2022 May 13.
6
Mucosal immune responses to infection and vaccination in the respiratory tract.呼吸道感染和疫苗接种的黏膜免疫应答。
Immunity. 2022 May 10;55(5):749-780. doi: 10.1016/j.immuni.2022.04.013.
7
Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant.分析 mRNA 疫苗诱导的 RBD 特异性记忆 B 细胞揭示了 SARS-CoV-2 奥密克戎变异株的强烈但不完全的免疫逃逸。
Immunity. 2022 Jun 14;55(6):1096-1104.e4. doi: 10.1016/j.immuni.2022.04.002. Epub 2022 Apr 7.
8
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
9
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.呼吸道黏膜递呈的新一代 COVID-19 疫苗可对 SARS-CoV-2 的原始株和变异株提供强大保护。
Cell. 2022 Mar 3;185(5):896-915.e19. doi: 10.1016/j.cell.2022.02.005. Epub 2022 Feb 9.
10
Intranasal COVID-19 vaccines: From bench to bed.鼻内 COVID-19 疫苗：从实验室到临床。
EBioMedicine. 2022 Feb;76:103841. doi: 10.1016/j.ebiom.2022.103841. Epub 2022 Jan 24.